Antibacterials developed to target a single organism: Mechanisms and frequencies of reduced susceptibility to the novel anti-Clostridium difficile compounds fidaxomicin and LFF571

Cold Spring Harbor Perspectives in Medicine

Volumn 6, Issue 2, 2016, Pages

  Leeds, Jennifer A ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; EFROTOMYCIN; ELONGATION FACTOR TU; FIDAXOMICIN; GE 2270A; LFF 571; MOCIMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; THIAZOLE DERIVATIVE;

AMINO ACID SUBSTITUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL SURVIVAL; CLINICAL PRACTICE; GENE PRODUCT; IN VITRO SELECTION; IN VITRO STUDY; MACROMOLECULE; MIC90; MINIMUM INHIBITORY CONCENTRATION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PROTEIN SYNTHESIS; RNA TRANSLATION; SINGLE NUCLEOTIDE POLYMORPHISM; SPONTANEOUS MUTATION; TREATMENT FAILURE; VIRUS CULTURE; CHEMISTRY; CLOSTRIDIUM INFECTIONS; DRUG EFFECTS; GENETICS; GENOTYPE; HUMAN; MICROBIAL SENSITIVITY TEST; MUTATION;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; THIAZOLES;

EID: 84956649038     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a025445     Document Type: Article

References (79)

1. Adams HM, Li X, Mascio C, Chesnel L, Palmer KL. 2015. Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus species. Antimicrob Agents Chemother 59: 4139-4147.
2. Allen CA, Babakhani F, Sears P, Nguyen L, Sorg JA. 2013. Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores. Antimicrob Agents Chemother 57: 664-667.
3. Artsimovitch I, Seddon J, Sears P. 2012. Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis. Clin Infect Diseases 55: S127-S131.
4. Babakhani F, Gomez A, Robert N, Sears P. 2011. Killing kinetics of fidaxomicin and its major metabolite, OP- 1118, against Clostridium difficile. J Med Microbiol 60: 1213-1217.
5. Babakhani F, Seddon J, Sears P. 2014. Comparative microbiological studies of transcription inhibitors fidaxomicin and the rifamycins in Clostridium difficile. Antimicrob Agents Chemother 58: 2934-2937.
6. Bagdasarian N, Rao K, Malani PN. 2015. Diagnosis and treatment of Clostridium difficile in adults: A systematic review. JAMA 313: 398-408.
7. Bauer MP, Kuijper EJ, van Dissel JT. 2009. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 15: 1067-1079.
8. Bedeschi A, Fonte P, Fronza G, Fuganti C, Serra S. 2014. The co-identity of lipiarmycin A3 and tiacumicin B. Nat Prod Commun 9: 237-240.
9. Bhansali SG, Mullane K, Ting LS, Leeds JA, Dabovic K, Praestgaard J, Pertel P. 2015. Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections. Antimicrob Agents Chemother 59: 1441-1445.
10. Butler MS. 2005. Natural products to drugs: Natural product derived compounds in clinical trials. Nat Prod Rep 22: 162-195.
11. Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ. 2012. Comparative in vitro activities of LFF571 against Clos- tridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria. Antimicrob Agents Chemother 56: 2493-2503.
12. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31: 431-455.
13. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S. 2012. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 12: 281-289.
14. Coronelli C, White RJ, Lancini GC, Parenti F. 1975. Lipiarmycin, a new antibiotic from Actinoplanes. II: Isolation, chemical, biological and biochemical characterization. J Antibiot (Tokyo) 28: 253-259.
15. Debast SB, Bauer MP, Sanders IM, Wilcox MH, Kuijper EJ. 2013. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: Clinical and therapeutic implications. J Antimicrob Chemother 68: 1305-1311.
16. Debast SB, Bauer MP, Kuijper EJ. 2014. European Society of Clinical Microbiology and Infectious Diseases:Update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20: 1-26.
17. Deibel MR Jr, Bodnar AL, Yem AW, Wolfe CL, Heckaman CL, Bohanon MJ, Mathews WR, Sweeney MT, Zurenko GE, Marotti KR, et al. 2004. Immobilization of a novel antibacterial agent on solid phase and subsequent isolation of EF-Tu. Bioconjug Chem 15: 333-343.
18. Deng GLL, Palestrant DJ, Whitehead L, Sachdeva M, Dzink- Fox J, LaMarche MJ, Leeds JA. 2011. Investigation of mode of binding of elongation factor Tu inhibitor LFF571. In 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL.
19. Evans CT, Safdar N. 2015. Current trends in the epidemiology and outcomes of Clostridium difficile infection. Clin Infect Dis 60: S66-S71.
20. Eyre DW, Babakhani F, Griffiths D, Seddon J, Del Ojo Elias C, Gorbach SL, Peto TE, Crook DW, Walker AS. 2014. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile. J Infect Dis 209: 1446-1451.
21. Fahnestock S, Weissbach H, Rich A. 1972. Formation of a ternary complex of phenyllactyl-tRNA with transfer factor Tu and GTP. Biochim Biophys Acta 269: 62-66.
22. Freeman J, Vernon J, Morris K, Nicholson S, Todhunter S, Longshaw C, Wilcox MH. 2015. Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes. Clin Microbiol Infect 21: 248.e9-248.e16.
23. Furano AV. 1975. Content of elongation factor Tu in Escherichia coli. Proc Natl Acad Sci 72: 4780-4784.
24. Goldstein EJ, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN. 2011. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother 55: 5194-5199.
25. Goldstein EJ, Babakhani F, Citron DM. 2012. Antimicrobial activities of fidaxomicin. Clin Infect Dis 55: S143-S148.
26. Gualtieri M, Villain-Guillot P, Latouche J, Leonetti JP, Bastide L. 2006. Mutation in the Bacillus subtilis RNA polymerase b0-subunit confers resistance to lipiarmycin. Antimicrob Agents Chemother 50: 401-402.
27. Gualtieri M, Tupin A, Brodolin K, Leonetti JP. 2009. Frequency and characterisation of spontaneous lipiarmycinresistant Enterococcus faecalis mutants selected in vitro. Int J Antimicrob Agents 34: 605-606.
28. Healy VL, Lessard IA, Roper DI, Knox JR, Walsh CT. 2000. Vancomycin resistance in enterococci: Reprogramming of the D-ala-D-Ala ligases in bacterial peptidoglycan biosynthesis. Chem Biol 7: R109-R119.
29. Hecht DOD, Gerding D. 2012. Activity of LFF571 against 103 clinical isolates of C. difficile. In 22nd European Congress on Clinical Microbiology and Infectious Diseases. London, UK.
30. Heffron SE, Jurnak F. 2000. Structure of an EF-Tu complex with a thiazolyl peptide antibiotic determined at 2.35 A resolution: Atomic basis for GE2270A inhibition of EFTu. Biochemistry 39: 37-45.
31. Hensgens MP, Dekkers OM, Demeulemeester A, Buiting AG, Bloembergen P, van Benthem BH, Le Cessie S, Kuijper EJ. 2014. Diarrhoea in general practice: When should a Clostridium difficile infection be considered? Results of a nested case-control study. Clin Microbiol Infect 20: O1067-O1074.
32. Ishihama Y, Schmidt T, Rappsilber J, Mann M, Hartl FU, Kerner MJ, Frishman D. 2008. Protein abundance profiling of the Escherichia coli cytosol. BMC Genomics 9: 102.
33. Ivarsson ME, Leroux JC, Castagner B. 2015. Investigational new treatments for Clostridium difficile infection. Drug Discov Today 20: 602-608.
34. Jaskunas SR, Lindahl L, Nomura M. 1975. Identification of two copies of the gene for the elongation factor EF-Tu in E. coli. Nature 257: 458-462.
35. Jayasekera MM, Onheiber K, Keith J, Venkatesan H, Santillan A, Stocking EM, Tang L, Miller J, Gomez L, Rhead B, et al. 2005. Identification of novel inhibitors of bacterial translation elongation factors. Antimicrob Agents Chemother 49: 131-136.
36. Ke D, Boissinot M, Huletsky A, Picard FJ, Frenette J, Ouellette M, Roy PH, Bergeron MG. 2000. Evidence for horizontal gene transfer in evolution of elongation factor Tu in enterococci. J Bacteriol 182: 6913-6920.
37. Kurabachew M, Lu SH, Krastel P, Schmitt EK, Suresh BL, Goh A, Knox JE, Ma NL, Jiricek J, Beer D, et al. 2008. Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis. J Antimicrob Chemother 62: 713-719.
38. LaMarche MJ, Leeds JA, Amaral A, Brewer JT, Bushell SM, Deng G, Dewhurst JM, Ding J, Dzink-Fox J, Gamber G, et al. 2012. Discovery of LFF571: An investigational agent for Clostridium difficile infection. JMed Chem 55: 2376-2387.
39. Landini P, Soffientini A, Monti F, Lociuro S, Marzorati E, Islam K. 1996. Antibiotics MDL 62,879 and kirromycin bind to distinct and independent sites of elongation factor Tu (EF-Tu). Biochemistry 35: 15288-15294.
40. Leeds JA, Sachdeva M, Mullin S, Dzink-Fox J, Lamarche MJ. 2012.Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571. Antimicrob Agents Chemother 56: 4463-4465.
41. Leeds JA, Sachdeva M, Mullin S, Barnes SW, Ruzin A. 2014. In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin. J Antimicrob Chemother 69: 41-44.
42. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, et al. 2015. Burden of Clostridium difficile infection in the United States. N Engl J Med 372: 825-834.
43. Locher HH, Caspers P, Bruyere T, Schroeder S, Pfaff P, Knezevic A, Keck W, Ritz D. 2014a. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother 58: 901-908.
44. Locher HH, Seiler P, Chen X, Schroeder S, Pfaff P, Enderlin M, Klenk A, Fournier E, Hubschwerlen C, Ritz D, et al. 2014b. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother 58: 892-900.
45. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364: 422-431.
46. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, Lynfield R, Maloney M, McAllister-Hollod L, Nadle J, et al. 2014.Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370: 1198-1208.
47. Mascio CT, Chesnel L, Thorne G, Silverman JA. 2014. Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 58: 3976-3982.
48. Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila VJ. 2013. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 37: 122-128.
49. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN. 2005. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353: 2433-2441.
50. Miller DL, Weissbach H. 1970. Interactions between the elongation factors: The displacement of GPD from the TU-GDP complex by factor Ts. Biochem Biophys Res Commun 38: 1016-1022.
51. Mohrle VG, Tieleman LN, Kraal B. 1997. Elongation factor Tu1 of the antibiotic GE2270A producer Planobispora rosea has an unexpected resistance profile against EF-Tu targeted antibiotics. Biochem Biophys Res Commun 230: 320-326.
52. Morris RP, Leeds JA, Naegeli HU, Oberer L, Memmert K, Weber E, LaMarche MJ, Parker CN, Burrer N, Esterow S, et al. 2009. Ribosomally synthesized thiopeptide antibiotics targeting elongation factor Tu. J Am Chem Soc 131: 5946-5955.
53. Mullane K, Lee C, Bressler A, Buitrago M, Weiss K, Dabovic K, Praestgaard J, Leeds JA, Blais J, Pertel P. 2015. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrob Agents Chemother 59: 1435-1440.
54. Noren T, Wullt M, Akerlund T, Back E, Odenholt I, Burman LG. 2006. Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid. Antimicrob Agents Chemother 50: 3028-3032.
55. Noren T, Akerlund T, Wullt M, Burman LG, Unemo M. 2007. Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile. Antimicrob Agents Chemother 51: 1840-1843.
56. Omura S, Imamura N, Oiwa R, Kuga H, Iwata R, Masuma R, Iwai Y. 1986. Clostomicins, new antibiotics produced by Micromonospora echinospora subsp. armeniaca subsp. nov. I: Production, isolation, and physico-chemical and biological properties. J Antibiot (Tokyo) 39: 1407-1412.
57. Parmeggiani A, Nissen P. 2006. Elongation factor Tu-targeted antibiotics: Four different structures, two mechanisms of action. FEBS Lett 580: 4576-4581.
58. Reeves DS. 1987. The pharmacokinetics of fusidic acid. J Antimicrob Chemother 20: 467-476.
59. Sachdeva M, Leeds JA. 2015. Subinhibitory concentrations of LFF571 reduce toxin production by Clostridium difficile. Antimicrob Agents Chemother 59: 1252-1257.
60. Sears P, Crook DW, Louie TJ, Miller MA, Weiss K. 2012. Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis 55: S116-S120.
61. Seddon JBF, Sears P. 2012.Mutant prevention concentration of fidaxomicin for Clostridium difficile. In 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA.
62. Seddon JBF, Gomez A, Artsimovitch I, Sears P. 2011. RNA polymerase target modification in Clostridium difficile with reduced susceptibility to fidaxomicin. In 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL.
63. Sela S, Yogev D, Razin S, Bercovier H. 1989. Duplication of the tuf gene: A new insight into the phylogeny of eubacteria. J Bacteriol 171: 581-584.
64. Selva E, Beretta G, Montanini N, Saddler GS, Gastaldo L, Ferrari P, Lorenzetti R, Landini P, Ripamonti F, Goldstein BP, et al. 1991. Antibiotic GE2270 a: A novel inhibitor of bacterial protein synthesis. I: Isolation and characterization. J Antibiot (Tokyo) 44: 693-701.
65. Selva E, Montanini N, Stella S, Soffientini A, Gastaldo L, Denaro M. 1997. Targeted screening for elongation factor Tu binding antibiotics. J Antibiot (Tokyo) 50: 22-26.
66. Sergio S, Pirali G, White R, Parenti F. 1975. Lipiarmycin, a new antibiotic from Actinoplanes. III: Mechanism of action. J Antibiot (Tokyo) 28: 543-549.
67. Sonenshein AL, Alexander HB, Rothstein DM, Fisher SH. 1977. Lipiarmycin-resistant ribonucleic acid polymerase mutants of Bacillus subtilis. J Bacteriol 132: 73-79.
68. Srivastava A, Talaue M, Liu S, Degen D, Ebright RY, Sineva E, Chakraborty A, Druzhinin SY, Chatterjee S, Mukhopad-hyay J, et al. 2011. New target for inhibition of bacterial RNA polymerase: “Switch region.” Curr Opin Microbiol 14: 532-543.
69. Stark H, Rodnina MV, Rinke-Appel J, Brimacombe R, Wintermeyer W, van Heel M. 1997. Visualization of elongation factor Tu on the Escherichia coli ribosome. Nature 389: 403-406.
70. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. 2013. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108: 478-498; quiz 499.
71. Swanson RN, Hardy DJ, Shipkowitz NL, Hanson CW, Ramer NC, Fernandes PB, Clement JJ. 1991. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob Agents Chemother 35: 1108-1111.
72. Tavecchia P, Gentili P, Kurz M, Sottani C, Bonfichi R, Lociuro S, Selva E. 1994. Revised structure of the antibiotic GE 2270A. J Antibiot (Tokyo) 47: 1564-1567.
73. Tavecchia P, Gentili P, Kurz M, Sottani C, Bonfichi R, Selva E, Locurio S, Restelli E, Ciabatti R. 1995. Degradation studies of antibiotic MDL 62,879 (GE2270A) and revision of the structure. Tetrahedron 51: 4867-4890.
74. Theriault RJ, Karwowski JP, Jackson M, Girolami RL, Sunga GN, Vojtko CM, Coen LJ. 1987. Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I: Taxonomy, fermentation and antibacterial activity. J Antibiot (Tokyo) 40: 567-574.
75. Ting LS, Praestgaard J, Grunenberg N, Yang JC, Leeds JA, Pertel P. 2012. A first-in-human, randomized, doubleblind, placebo-controlled, single- and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers. Antimicrob Agents Chemother 56: 5946-5951.
76. Tsutsumi LS, Owusu YB, Hurdle JG, Sun D. 2014. Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review. Curr Top Med Chem 14: 152-175.
77. Voorhees RM, Ramakrishnan V. 2013. Structural basis of the translational elongation cycle. Annu Rev Biochem 82: 203-236.
78. Yin N, Li J, He Y, Herradura PS, Pearson A, Mesleh MF, Mascio CT, Howland K, Steenbergen J, Thorne GM, et al. 2015. Structure-activity relationship studies of a series of semi-synthetic lipopeptides leading to the discovery of surotomycin, a novel cyclic lipopeptide being developed for the treatment of Clostridium difficile-associated diarrhea. J Med Chem 58: 5137-5142.
79. Zuurmond AM, Martien de Graaf J, Olsthoorn-Tieleman LN, van Duyl BY, Morhle VG, Jurnak F, Mesters JR, Hilgenfeld R, Kraal B. 2000. GE2270A-resistant mutations in elongation factor Tu allow productive aminoacyl-tRNA binding to EF-Tu.GTP.GE2270A complexes. J Mol Biol 304: 995-1005.